Cel­gene-part­nered An­ten­gene preps new Chi­na deals as $21M round lands

Just a few months af­ter ink­ing a deal to de­vel­op one of Cel­gene’s ex­per­i­men­tal can­cer drugs for the Chi­nese mar­ket, An­ten­gene has un­veiled a $21 mil­lion A round to help pay for the work.

An­ten­gene bears some clas­sic marks of a Chi­na-based start­up. Its CEO is Jay Mei, who held a se­nior de­vel­op­ment po­si­tion with Cel­gene and spear­head­ed Revlim­id’s ap­proval in Chi­na. Cel­gene, mean­while, took an eq­ui­ty stake in the com­pa­ny as it passed over Asian rights to its TORC1/2 in­hibitor CC-223.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.